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Background/aim: Myocardial protection is an important factor of open heart surgery and biological biomarkers (lactate, CKMB, cardiac
troponin I, and pyruvate) are used to assess myocardial damage. This study compares the effects of dexmedetomidine and remifentanil
on myocardial protection during coronary artery bypass grafting (CABG) surgery.
Materials and methods: Patients scheduled for elective CABG surgery (n = 60) were included in this study. Anesthesia induction was
introduced with propofol, fentanyl, and vecuronium bromide. Anesthesia was maintained with remifentanil infusion and sevoflurane
in the remifentanil group (Group R) and with dexmedetomidine infusion and sevoflurane in the dexmedetomidine group (Group D).
Blood samples for biochemical markers were taken from the coronary sinus catheter before cardiopulmonary bypass (T1), 20 min after
aortic cross-clamping (T2), 20 min after removal of the aortic cross-clamping (T3), and 10 min after separation from cardiopulmonary
bypass (T4).
Results: Demographic data were similar between the groups. Lactate level at the T2 period and CKMB levels during the study period
were lower in Group D than in Group R. In both groups, all values except pyruvate significantly increased over time.
Conclusion: The dexmedetomidine-sevoflurane combination may improve the cardioprotective effect in comparison with remifentanilsevoflurane in CABG surgery.
Key words: Dexmedetomidine, myocardial protection, remifentanil, sevoflurane

1. Introduction
Myocardial protection is important in preventing the
damaging effects of a cardiopulmonary bypass (CPB) on
the myocardium, including ischemic and reperfusion
injury (1). Eliminating or reducing myocardial injury
can improve the clinical prognosis of patients undergoing
cardiac surgery. Cardiac biomarkers are associated with
the degree of cardiac injury and cardiac troponin I (cTnI),
lactate, and creatine phosphokinase-MB (CKMB) are
especially sensitive biomarkers for evaluating cardiac cell
damage (2–4). Pyruvate, lactate, glucose, and insulin are
respiratory substrates indicating heart perfusion. The level
of pyruvate in the blood increases in the anaerobic state
and pyruvate is converted to lactate under these conditions
(3–5).

Sevoflurane, a potent inhalation agent, decreases the
inflammatory response and improves myocardial function
after CPB (6). Dexmedetomidine, a selective and specific
α-2 adrenoceptor agonist, has been frequently used as a
sedative or adjuvant anesthetic drug in cardiac surgery.
Dexmedetomidine has also been known to have some
neuroprotective effects; however, data are insufficient for
its cardioprotective effects in human studies. Remifentanil,
a fast-acting opioid, has been generally used in cardiac
surgery for cardiac protection before sternotomy (7).
This study compared the cardiac effects of sevoflurane
plus dexmedetomidine with those of sevoflurane plus
remifentanil during adult cardiac surgery with CPB by
examining levels of lactate, pyruvate, CKMB, and cTnI in
patient blood samples. The hypothesis is that a difference
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would be seen between dexmedetomidine and remifentanil
as an adjuvant anesthetic drug for cardiac surgery in terms
of their myocardial protective effects.
2. Materials and methods
2.1. Patients
After approval by the local ethics committee (Çukurova
University; 20 June 2013; Approval No. 20/9) and clinical
trials (NCT02405689), written informed consent was
obtained from the patients (n = 60) for this prospective
randomized study conducted between December 2014
and August 2015. The patients were between the age of 18
and 70 years, scheduled for elective CABG surgery, and
had physical status of II–III according to the American
Society of Anesthesiologists. The exclusion criteria were
emergency surgery, prior cardiac surgery (reoperation),
ejection fraction less than 50%, moderate or severe chronic
restrictive or obstructive pulmonary disease, hypoxia (SpO2
< 90% in room air), preoperative mechanical ventilation,
intraaortic balloon pump, inotropic agent requirement,
chronic liver disease, or renal failure (creatinine > 1.6 mg/
dL), bradycardia (heart rate < 50 beats/min), chronic atrial
fibrillation, or elevated levels of cardiac enzyme within 48
h before surgery.
All preoperative cardiac medication was continued
until the day of surgery. Premedication was provided
intravenously (iv) with 0.02 mg/kg midazolam
to all patients 30 min before surgery. A five-lead
electrocardiogram, invasive arterial blood pressure, and
pulse oximetry monitoring were applied to all patients
in the operating room. After 2 mL of 0.2% lidocaine was
injected subcutaneously, a radial arterial catheter was
inserted for continuous blood pressure monitoring.
Anesthesia was induced with 1 mg/kg propofol iv
and 1 µg/kg fentanyl iv for all patients. Vecuronium
bromide (0.1 mg/kg) was given to facilitate endotracheal
intubation and additional doses of 0.03 mg/kg were
administered during CPB. A central venous catheter
(internal jugular or subclavian) and an esophageal heat
probe were inserted after tracheal intubation. The same
surgery team operated on all the patients. The surgeries
took place under cardiac arrest with CPB. The surgical
steps were standardized with median sternotomy and
pericardiotomy. Methylprednisolone (5 mg/kg) was
administered to decrease the CPB-related inflammatory
response in all patients. Unfractionated heparin (300 U/
kg, iv) was given to achieve an activated clotting time
(ACT) of more than 480 s during CPB. If the ACT was less
than 480 s, an additional dose of heparin (100 U/kg) was
given during CPB. CPB was started after aortic and venous
cannulas had been inserted. Myocardial protection was
achieved with intermittent blood cardioplegia, repeated in
intervals of 20–25 min. We drew 400 mL of blood from
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the heart–lung pump and potassium chloride was added
to the cardioplegia solution as K+ level 16 mEq/L. There
was no additional drug (such as NaHCO3 or mannitol) in
the cardioplegia solution, except potassium. The amount
of potassium chloride added was calculated with the
following formula:
added potassium (mEq) = [16 – measured potassium
(mEq/L)] × 0.4.
An antifibrinolytic agent (aprotinin or tranexamic
acid) was not used during the surgery. At the end of the
CPB, 1.5 mg of protamine sulfate (iv) per 100 U of iv
heparin was used to reverse the anticoagulation effect.
The patients were divided into two groups with
computer-generated randomization: a remifentanil group
(Group R, n = 30) and a dexmedetomidine group (Group
D, n = 30). In Group R, anesthesia was maintained with
0.5%–1.5% sevoflurane in a 50%/50% oxygen/air mixture
and 0.125–0.25 µg/kg/min remifentanil infusion after a 1
µg/kg/10 min loading dose of remifentanil. In Group D,
anesthesia was maintained with 0.5%–1.5% sevoflurane
in a 50%/50% oxygen/air mixture and 0.3–0.9 µg/kg/
min dexmedetomidine infusion after a 0.5 µg/kg/10 min
loading dose of dexmedetomidine. The drugs were diluted
to 100 mL in 0.9% NaCl (the final volume was 100 mL
= drugs + NaCl), and the prepared infusions were given
to the patients by an investigator blinded to the patients’
group designations. The infusions were discontinued at
the end of the surgery and the patients were transferred
to the intensive care unit intubated and fully monitored.
Nitroglycerin infusion (0.5–2 µg/kg/min) was used for
all patients during CPB and the infusion rate was titrated
to maintain a mean perfusion pressure of 50–80 mmHg.
During the rewarming period, 0.2 mg/kg midazolam
was administered to the patients. Hematocrit values were
maintained at 25%–28% during the CPB period and
above 30% in the post-CPB period. The nitroglycerin
infusion, sevoflurane concentration, fluid replacement,
and ephedrine rates were adjusted to maintain optimal
blood pressure (mean arterial pressure = 50–65 mmHg)
during CPB, if needed. After CPB, fluid replacement was
performed and dopamine infusion (5–10 µg/kg/min) was
started if the mean arterial pressure dropped below 60
mmHg according to clinical conditions.
Mean arterial pressure (MAP) and arterial blood gas
analysis were observed and recorded during surgery.
All blood samples, including lactate, pyruvate, CKMB,
and cTnI, were taken via the coronary sinus catheter at
specific times. The aortic cross-clamping time, CPB time,
extubation time, and length of stay in the intensive care
unit (ICU) and hospital were recorded.
2.2. Blood samples
Blood samples for biochemical markers were taken from
the patients via coronary sinus catheter at four time-
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points: before CPB (as soon as the coronary sinus catheter
was inserted, T1), 20 min after aortic cross-clamping (T2),
20 min after removal of the aortic cross-clamping (T3),
and 10 min after separation from CPB (T4).
The blood samples were drawn from the patients and
collected in EDTA tubes and 5-mL vacuum collection
tubes without anticoagulant for serum separation (Becton
Dickinson Vacutainer, Ref. 369032) under standardized
conditions to minimize sources of preanalytical variation.
All blood samples with visible hemolysis were discarded.
The EDTA samples (under appropriate conditions)
were used for the lactate test without waiting. The tubes
without anticoagulant were allowed to clot at room
temperature for 15–20 min, separated by centrifugation
at 3000 × g for 10 min, and kept refrigerated if analyzed
within 12 h. Otherwise, the samples were frozen at −80
°C and analyzed within 1 year. When all of the specimens
were available, they were thawed, mixed, centrifuged
again at 3000 × g for 10 min, and then analyzed at room
temperature.
The lactate plasma analyte was analyzed colorimetrically.
The analysis was performed with a Beckman Coulter
kit (Cat. No. 445875) on the Beckman UniCel DXC 800
Synchron autoanalyzer (Beckman Coulter Inc., CA,
USA). The cTnI and CKMB serum analytes were analyzed
via chemiluminescent immunoassay. The analysis was
performed with Beckman Coulter kits (Cat. No. A78803
and Cat. No. 386371, respectively) on the Beckman
Coulter Access 2 Immunoassay System fully automatized
autoanalyzer (Beckman Coulter Inc.). Finally, the pyruvate
serum analyte was analyzed with a colorimetric assay (λ
= 570 nm). The analysis was carried out with a pyruvate
assay kit (Cat No. ab65342, Abcam, Cambridge, UK) and

BioTek Instruments (Winooski, VT, USA). The detection
range of this kit was 40–200 µM, version 9, last updated 30
April 2015 (www.abcam.com).
2.3. Statistical analysis
All analyses were performed using SPSS 20.0 (IBM Corp.,
Armonk, NY, USA). Categorical variables were expressed
as numbers and percentages, whereas continuous variables
were summarized as mean ± SD and as median plus
minimum–maximum where appropriate. The chi-square
test was used to compare categorical variables between
the groups. The normality of distribution for continuous
variables was confirmed with the Kolmogorov–Smirnov
test. For comparison of continuous variables between two
groups, Student’s t-test or the Mann–Whitney U test were
used, depending on whether the statistical hypotheses
were fulfilled or not. To evaluate the change in lactate,
CKMB, cTnI, and pyruvate levels over time, repeated
measurements analysis was applied. The statistical level of
significance for all tests was set to 0.05.
2.4. End points
The primary end points were the blood levels of lactate,
pyruvate, CKMB, and cTnI. The secondary end points
were extubation time and length of stay in the ICU.
3. Results
Demographic data (age, sex, and weight), duration of CPB,
aortic cross-clamping time, extubation time, length of
ICU and hospital stay, and arterial blood gas analyses were
similar between the groups (P > 0.05) (Tables 1 and 2).
In both groups, coronary sinus lactate release increased
progressively over time (P < 0.001 and P = 0.006), but it
was higher in the T2 period in Group R than in Group D
(P = 0.03) (Table 3).

Table 1. Demographic data, CPB, and cross clamping time of the groups.
Group R (n = 30)
(mean ± SD)

Group D ( n = 30)
(mean ± SD)

P

Age (years)

53.90 ± 15.43

59.83 ± 14.22

0.13

Sex (female/male)

9/21

13/17

0.42

Weight (kg)

75.33 ± 13.31

76.93 ± 16.27

0.68

CPB time (min)

119.60 ± 34.77

114.33 ± 34.88

0.56

Cross clamping time (min)

78.36 ± 21.66

74.00 ± 25.83

0.48

Extubation time (h)

6.23 ± 3.98

6.73 ± 3.48

0.61

Length of ICU stay (day)

3.50 ± 2.62

3.16 ± 0.98

0.52

Length of hospital stay (day)

8.86 ± 3.10

10.60 ± 4.08

0.07

Data are presented as mean ± SD (standard deviation) or as the number of patients. Group R: Remifentanil
group; Group D: dexmedetomidine group; CPB: cardiopulmonary bypass; ICU: intensive care unit.
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Table 2. Mean arterial pressure and arterial blood gas analysis of the groups.
Group R (n = 30)
(mean ± SD)

Group D ( n = 30)
(mean ± SD)

P

MAP
T1
T2
T3
T4

65.30 ± 11.55
59.13 ± 9.92
54.07 ± 13.20
65.00 ± 8.10

67.27 ± 14.04
58.97 ± 9.32
57.10 ± 9.85
64.60 ± 7.98

0.68
0.87
0.38
0.87

pH
T1
T2
T3
T4

7.38 ± 0.07
7.34 ± 0.05
7.33 ± 0.05
7.32 ± 0.06

7.34 ± 0.06
7.30 ± 0.06
7.31 ± 0.05
7.29 ± 0.07

0.49
0.54
0.73
0.95

PaO2
T1
T2
T3
T4

211.87 ± 69.30
254.80 ± 53.70
255.83 ± 53.77
200.31 ± 85.40

186.54 ± 75.85
268.17 ± 44.40
267.13 ± 39.82
189.78 ± 91.92

0.18
0.30
0.36
0.65

PaCO2
T1
T2
T3
T4

35.15 ± 5.46
36.50 ± 3.25
36.00 ± 2.86
35.46 ± 5.65

33.77 ± 5.55
35.95 ± 3.52
35.28 ± 3.74
35.58 ± 4.37

0.79
0.79
0.26
0.27

HCO3
T1
T2
T3
T4

21.50 ± 2.18
20.25 ± 1.92
19.23 ± 1.49
18.25 ± 1.52

19.37 ± 3.02
18.59 ± 2.47
18.49 ± 1.73
17.61 ± 2.26

0.21
0.41
0.50
0.23

Data are presented as mean ± SD (standard deviation). Group R: Remifentanil group; Group D: dexmedetomidine
group; MAP: mean arterial pressure; T1: before CPB; T2: 20 min after aortic cross-clamping; T3: 20 min after
removal of the aortic cross-clamping; T4: 10 min after separation from CPB.

CKMB levels were raised in both groups (P < 0.001 and
P = 0.008), but this rise was significantly higher in Group
R than in Group D at the four time-points (P = 0.03, P =
0.01, P = 0.04, and P = 0.03, respectively) (Table 3).
cTnI release increased consistently in both groups over
time (P < 0.001 and P = 0.011) and there were no significant
differences between the groups (P > 0.05) (Table 3).
Finally, the pyruvate levels remained unchanged
during the sampling period and no differences were seen
between the groups (P > 0.05) (Table 3).
4. Discussion
In this study comparing two anesthetic techniques,
the CKMB levels in all study periods and the lactate
levels in the T2 period were lower in the sevofluranedexmedetomidine group than in the sevofluraneremifentanil group. However, no differences were seen in
extubation time, length of ICU, or hospital stay.
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Cardiac surgery with the CPB procedure is associated
with ischemia/reperfusion injury. Some techniques
should be performed to prevent organ injury, such as
systemic and/or topical hypothermia. One such method
is cardioplegia, which minimizes myocardial damage
during this stressful period. In addition, the choice of
anesthetic agent may help in cardiac protection. Balanced
anesthesia techniques (a potent volatile anesthetic and
an adjuvant agent) are generally performed for fast-track
adult cardiac surgery. Therefore, balanced anesthesia
techniques with sevoflurane-remifentanil and sevofluranedexmedetomidine were selected for this study.
Cardiac biomarkers cTnI, lactate, and CKMB can be
indicators of cardiac injury, and coronary sinus blood
sampling can be used to evaluate early myocardial release
for these cardiac biomarkers (2–4). In particular, cTnI is a
highly specific and sensitive biomarker for myocardial cell
injury (2). Kapoor et al. showed that pyruvate is a myocardial
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Table 3. Lactate, CKMB, cTnI, and pyruvate values of the groups.
Group R (n = 30),
median (min–max)

Group D ( n = 30),
median (min–max)

P

Lactate (mmol/L)
T1
T2
T3
T4

2.95 (1.45–14.60)
4.30 (2.07–14.80)
4.50 (2.10–12.50)
4.40 (2.04–15.00)

2.40 (1.14–22.26)
3.13 (1.40–15.10)
4.19 (1.55–23.46)
3.95 (1.61–27.45)

0.10
0.03*
0.38
0.35

P

<0.001*

0.006*

CKMB (mg/L)
T1
T2
T3
T4

5.30 (0.01–18.00)
11.75 (1.30–155.70)
22.75 (3.00–82.80)
30.60 (5.40–91.30)

2.60 (1.60–31.60)
5.80 (2.60–194.30)
15.00 (5.10–250.90)
20.25 (9.30–97.20)

P

<0.001*

0.008*

cTnI (mg/L)
T1
T2
T3
T4

0.15 (0.00–2.09)
0.50 (0.06–11.20)
1.03 (0.18–14.61)
1.90 (0.30–11.59)

0.07 (0.01–31.18)
0.20 (0.05–28.32)
1.07 (0.21–30.02)
1.29 (0.33–34.51)

P

0.001*

0.011*

Pyruvate (mmol/L)
T1
T2
T3
T4

0.02 (0.01–0.03)
0.02 (0.01–0.07)
0.03 (0.01–0.09)
0.03 (0.01–0.09)

0.01 (0.01–0.05)
0.02 (0.01–0.05)
0.02 (0.02–0.09)
0.02 (0.01–0.06)

P

>0.05

>0.05

0.03*
0.01*
0.04*
0.03*

0.40
0.33
0.91
0.70

0.74
0.71
0.52
0.24

Data are presented as median (min–max). CKMB: Creatine phosphokinase-MB; cTnI: cardiac troponin I; T1:
before CPB; T2: 20 min after aortic cross-clamping, T3: 20 min after removal of the aortic cross-clamping; T4:
10 minutes after separation from CPB. *: Statistically significant.

biomarker for predicting postoperative outcome along
with lactate, cTnI, and CKMB (3). In addition, they
claimed that pre-CPB myocardial lactate (2.9 mmol/L)
and pyruvate (0.07 mmol/L) levels can be used to estimate
the post-CPB inotropic agent requirement (3). With this in
mind, pyruvate was added to cTnI, lactate, and CKMB as a
cardiac biomarker from the coronary sinus blood samples
in our study. Although the lactate values were higher than
2.9 mmol/L and the pyruvate values were lower than 0.07
mmol/L in both groups, the extubation time, length of
ICU and hospital stay, and inotropic requirements were
similar between the groups in this study.
Dexmedetomidine may be used as an adjuvant
anesthetic drug during cardiac surgery. It is preferred due to
its antiarrhythmic, cardioprotective, delirium therapeutic,
and analgesic effects (8). Several animal studies have
shown that dexmedetomidine protects against ischemia/
reperfusion injury in the heart, brain, kidneys, and lungs

(9–13). It may also improve the coronary artery blood flow
and reduce lactate levels in ischemia models in animals
(13–15). Okada et al. demonstrated that dexmedetomidine
improved global infarct size in a rat heart model (13). Ji
et al. showed an improvement in mortality rate with iv
dexmedetomidine infusion in patients undergoing CABG
surgery (9). Riha et al. found that the coadministration
of dexmedetomidine-ketamine was associated with
lower blood levels of cTnI and CKMB than sevofluranesufentanil anesthesia in patients undergoing elective
CABG surgery (16).
Opioids are commonly used as adjuvant anesthetic
drugs in cardiac surgery. Recently, opioids have been
shown to provide an opioid-induced cardioprotection
via the δ-opioid receptor on cardiac myocytes (17–19).
In some animal and human studies, the δ-opioid receptor
stimulation produced K-dependent ATP channel
activation, and this mechanism seems to be responsible for
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the potent cardioprotective effect (20–22). Moreover, Irwin
et al. stated that cardiac opioid receptors (delta-1, kappa)
are responsible for opioid-induced cardioprotection via
protein kinase C activation and the potassium channel
(23).
Remifentanil may be useful for cardiac patients due to
its rapid elimination and noncumulative effect properties.
Wong et al. showed that several cardiac biomarkers (creatine
kinase, cTnI, ischemia-modified albumin, heart-type fatty
acid-binding protein, etc.) decreased in cardiac patients
using remifentanil (7). When comparing the cardiac
protective effect of remifentanil with fentanyl, lower CKMB
and troponin T levels were observed with remifentanil
(24,25). In this study, CKMB levels and lactate levels at T2
were lower in the sevoflurane-dexmedetomidine group
than in the sevoflurane-remifentanil group at all times.
However, no differences were seen between the groups for
the other values.
This study has certain limitations. First, blood
samples were taken through a coronary sinus catheter
for more accurate early information. Consequently, the
intraoperative and postoperative levels of lactate, pyruvate,
cTnI, and CKMB values were not compared. Therefore,

the effects of dexmedetomidine and remifentanil on
postoperative biomarkers could not be investigated.
Moreover, only patients from a certain time period
(December 2014–August 2015) were included this study;
for this reason, the sample size was small (n = 60). Finally,
the echocardiographic comparison of the groups could be
useful for determining myocardial function after CPB.
In conclusion, the sevoflurane-dexmedetomidine
combination may produce more improved cardioprotective
effects compared with sevoflurane-remifentanil anesthesia.
Further prospective, multicenter, and randomized studies
with larger sample sizes are needed to compare the
cardioprotective effects of dexmedetomidine to those of
opioids.
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